Rare diseases are only rare if you don’t live with one.®
Today, rare diseases affect approximately 300 million people worldwide. While the diseases themselves are uncommon, the challenges associated with living with one are not.
Quoin Pharmaceuticals launched NETHERTON NOW, a campaign dedicated to raising awareness, fostering advocacy, and supporting patients and families affected by Netherton Syndrome.
VISIT THE WEBSITE: nethertonnow.com
Our Motivation
We are relentlessly focused on developing therapeutic products to address a range of rare diseases and we are humbled and inspired every day by the courage of patients, their families and their care teams.
Our Business Strategy
Patients are at the center of everything we do. To ensure our rare disease products reach every patient who needs them, no matter where they are in the world, we have established exclusive international marketing and distribution partnerships covering 60 countries to augment our own planned commercial infrastructure for the US and Europe.
Clinical Trials
Quoin Pharmaceuticals is conducting two ongoing clinical studies to evaluate QRX003 for the treatment of Netherton Syndrome under an open U.S. Investigational New Drug (IND).